Schedule

13:00 - 13:10
Introduction

JANETE MARIA CERUTTI

Presenter

RODRIGO MORENO REYES

Presenter

OMAR DARY

Chair

MARIA DEL CARMEN SILVA CROOME

Chair

13:10 - 13:30
Despite major progress, iodine deficiency remains a global health problem in 2025

RODRIGO MORENO REYES

Speaker

13:30 - 13:45
The history of the elimination of iodine deficiency disorders in the Americas

EDUARDO PRETELL

Speaker

13:45 - 14:00
Awareness and capacity building to sustain optimal iodine nutrition in Latin America

ANA MARÍA HIGA YAMASHIRO

Speaker

14:00 - 14:15
Effects of iodine intake on thyroid autoimmunity

ELIZABETH PEARCE

Speaker

14:15 - 14:30
Iodotyrosines as novel biomarkers for iodine deficiency

JOSÉ MORENO

Speaker

16:30 - 16:45
Strengthening design and surveillance of salt iodization to support safe and effective programs on thyroid function

OMAR DARY

Speaker

16:45 - 17:00
Not too little, not too much: the Chilean iodine fortification experience

LORENA MOSSO

Speaker

17:00 - 17:15
Iodine nutritional status in Brazil

HELTON ESTRELA RAMOS

Speaker

17:15 - 17:30
Iodine supplementation in pregnancy in Brazil

ROSALIA PADRO PADOVANI COLETTE

Speaker

17:30 - 17:45
The Danish investigation on iodine intake and thyroid disease (DanThyr): history and implications

LENA BJERGVED SIGURD

Speaker

17:45 - 18:00
Iodine status in Colombia and its possible association with thyroid autoimmunity

IVÁN DARÍO ESCOBAR DUQUE

Speaker

08:00 - 08:10
Introduction

SUSAN MANDEL

Presenter

EDUARDO TOMIMORI

Presenter

08:10 - 08:40
Basic Principles of Thyroid Ultrasound and Device Settings to Optimize Imaging

SARA AHMADI

Speaker

08:40 - 09:10
Ultrasound of Diffuse Thyroid Disorders

RUDOLF PFEILSTICKER

Speaker

09:10 - 09:40
Challenges in Thyroid Nodule Imaging

SUSAN MANDEL

Speaker

09:40 - 10:00
Assessment of Cervical Lymph Nodes

DEBORA DANILOVIC

Speaker

08:10 - 08:30
Navigating uncertainly: advancements in managing indeterminate thyroid nodules

DENISE MOMESSO

Speaker

08:30 - 08:45
RFA x MW – Nuances of indications and techniques

LEONARDO RANGEL

Speaker

08:45 - 09:00
Is thermal ablation safe for malignancies?

RAFAEL DE CICCO

Speaker

09:00 - 09:15
Expanding the indications for thermal ablations

ERIVELTO VOLPI

Speaker

09:15 - 09:30
Q&A

09:30 - 09:50
Effective surveillance strategies for micropapillary thyroid cancer: integrating surgical insight

MICHAEL TUTTLE

Speaker

09:50 - 10:05
Total thyroidectomy x Lobectomy (indications and follow-up)

SANTIAGO ZUND

Speaker

10:05 - 10:20
Defining the best preoperative apporoach for thyroid cancer

MARIKA RUSSELL

Speaker

10:20 - 10:30
Q&A

10:30 - 10:50
Artificial Intelligence for Evaluation of Thyroid Nodules

NAYKKY SINGH OSPINA

Speaker

10:50 - 11:10
Parathyroid Imaging

MAISIE SHINDO

Speaker

11:10 - 11:30
Nonthyroid neck pathology

LEONARDO RANGEL

Speaker

11:30 - 11:50
Techniques to Optimize Fine Needle Aspiration Biopsy

MARIO ARAUJO JUNIOR

Speaker

10:45 - 11:00
Medical management of GD: When is the time for RAI?

ADRIANO NAMO CURY

Speaker

11:00 - 11:15
Way and when Surgery for GD

EVANDRO VASCONCELOS

Speaker

11:15 - 11:30
Q&A

11:30 - 11:45
Autofluorescence and Parathyroid Vascular Assessment

MARCO DEMARCHI

Speaker

11:45 - 12:00
Remote thyroid access: breakthroughs and future directions in surgical innovation

RENAN B. LIRA

Speaker

13:00 - 13:15
Poorly Differentiated Thyroid Cancer – Contemporary Definitions and Management

MARK ZAFEREO

Speaker

13:15 - 13:30
Neoadjuvant Therapy for Advanced Disease

ANA HOFF

Speaker

13:30 - 13:45
Disparities in Access to Thyroid Care

LUIZ PAULO KOWALSKI

Speaker

13:45 - 14:00
Q&A

13:00 - 13:20
Correlation between ultrasound and thyroid cytology

FERNANDA FARO

Speaker

13:20 - 13:40
Patient demos - Examining phisician

BERNARDO LOPES CANÇADO FONSECA

Speaker

13:40 - 16:00
Presentation of clinical cases

LEONARDO RANGEL

Moderator

SUSAN MANDEL

Panelist

MAISIE SHINDO

Panelist

15:00 - 15:20
Metabolomics can be of help?

ANITA BOELEN

Speaker

15:20 - 15:40
Is neonatal diagnosis of Central Hypothyroidism worthy to be implemented?

HELTON ESTRELA RAMOS

Speaker

15:40 - 16:00
The changing spectrum of CH after the loweing of TSH thresholds

MARIA CRISTINA VIGONE

Speaker

16:00 - 16:20
Discussion

15:00 - 15:30
Animal Models

JOSEF KÖHRLE

Speaker

15:30 - 15:50
Discussion

15:00 - 15:20
Advances in structural biology

JANE SANDERS

Speaker

15:20 - 15:40
TSHR-IGF1R crosstalk

TERRY FRANCIS DAVIES

Speaker

15:40 - 16:00
Utility of TSHR antibodies in clinical practice-Graves'

GEORGE KAHALY

Speaker

16:00 - 16:20
Discussion

15:00 - 15:20
Structure and function of type 2 and type 3 deiodinase enzymes

ULRICH SCHWEIZER

Speaker

15:20 - 15:40
Thyroid hormone in non-alcohholic liver diseases

PAUL YEN

Speaker

15:40 - 16:00
Thyroid hormone and muscle differentiation

FLAVIA FONSECA BLOISE

Speaker

16:00 - 16:20
Discussion

16:20 - 16:35
1112237 - REAL-WORLD EXPERIENCE WITH LENVATINIB PLUS PEMBROLIZUMAB IN METASTATIC BRAF WILD-TYPE ANAPLASTIC THYROID CARCINOMA (BRAFWT-ATC) | Presenter: SARAH HAMIDI

16:35 - 16:50
1112402 - REDIFFERENTIATION OF REFRACTORY THYROID CANCER OF FOLLICULAR ORIGIN: NATIONAL FRENCH REAL LIFE EXPERIENCE | Presenter: LAMARTINA

16:50 - 17:05
1112371 - T3 ANALOGUE TRIIODOTHYROACETIC ACID (TRIAC) TREATMENT AND SURVIVAL IN MCT8 DEFICIENCY: AN INTERNATIONAL REAL-WORLD COHORT STUDY | Presenter: FLOOR VAN DER MOST

17:05 - 17:20
1112577 - TOTAL TRIIODOTHYRONINE AND TOTAL THYROXINE LEVELS ARE POSITIVELY ASSOCIATED WITH PREGNANCY LOSS OF CHROMOSOME NORMAL (EUPLOID) FETUSES | Presenter: SOFIE BLIDDAL

16:20 - 16:35
1112267 - CHARACTERIZATION OF PATIENT DERIVED XENOGRAFTS (PDX) MOUSE MODELS AND THEIR RESPECTIVE CELL LINES FROM ANAPLASTIC THYROID CANCER (ATC) | PRESENTER : MIRA SALEH

16:35 - 16:50
1112491 - ENDOCRINE DISRUPTORS MIXTURE IMPAIRS THYROID DIFFERENTIATION THROUGH EPIGENETIC MECHANISMS AND DYSREGULATED PKA AND AKT SIGNALING PATHWAYS | PRESENTER: GUILHERME HENRIQUE

16:50 - 17:05
1112483 - IMPACT OF MICROBIOTA-NLRP3 INFLAMMASOME INTERACTIONS ON PROGRESSION OF AUTOIMMUNE THYROIDITIS | PRESENTER: BOSHEN GONG

17:05 - 17:20
1112666 - REGULATION OF ADULT NEUROGLIOGENESIS BY DIO2 IN MOUSE BRAIN: A TALE OF TWO WAVES | PRESENTER: VICTOR VALCARCEL HERNÁNDEZ

16:20 - 16:35
1112615 - MECHANISMS IN THYROID EYE DISEASE (TED) - TSH RECEPTOR ANTIBODIES ENHANCE THE EXPRESSION OF BOTH TSH RECEPTORS AND IGF-1 RECEPTORS IN FIBROBLASTS. | PRESENTER: TERRY FRANCIS DAVIES

16:35 - 16:50
1112290- PD-L1 ACTIVATES INTRINSIC CELLULAR FUNCTIONS IN THYROID CELLS: IMPLICATIONS FOR IMMUNE CHECKPOINT INHIBITOR INDUCED THYROIDITIS | PRESENTER: MIHAELA STEFAN LIFSHITZ

16:50 - 17:05
1112488 - ROLE OF T3 IN DENDRITIC CELL ACTIVATION: INSIGHTS INTO THE METABOLIC REPROGRAMMING AND ITS FUNCTIONAL IMPACT | PRESENTER: ANTONELLA BLANCO

17:05 - 17:20
1112247 - THE ROLE OF TYPE 3 DEIODINASE IN A HUMAN MODEL FOR EARLY BRAIN DEVELOPMENT | PRESENTER: ANNA LOPEZ MARTI

17:30 - 17:40
Speech - LATS President

JANETE MARIA CERUTTI

Presenter

17:40 - 17:45
Speech - Presidents of ETA, AOTA, and ATA

17:45 - 17:50
Speech - Thyroid Federation International

17:50 - 18:00
Speech - LOC President

DENISE PIRES DE CARVALHO

Presenter

18:00 - 18:10
Speech - POC President

ANA LUIZA MAIA

Presenter

18:10 - 18:35
Advances in thyroid cancer management (LATS)

ANA HOFF

Speaker

18:35 - 19:00
What has changed in Thyroid Eye Disease? (ETA)

MARIO SALVI

Speaker

19:00 - 19:25
Surgical approach changes in thyroid cancer over the years (ATA)

JULIE SOSA

Speaker

19:25 - 19:50
Progress in Basic thyroid research: a 5 year overview (AOTA)

NORIYUKI KOIBUCHI

Speaker

07:00 - 08:25
Representative for ATA

LAURA BOUCAI

Panelist

07:00 - 08:25
Representative for AOTA

KENICHI-ITO

Panelist

07:00 - 08:25
Representative for ETA

SIMONE DE LEO

Panelist

07:00 - 08:25
Representative for LATS

FERNANDA VAISMAN

Panelist

09:45 - 10:30
My Journey in Thyroid Research

TANIA MARIA RUFFONI ORTIGA

Speaker

10:35 - 10:55
For the proposal

SOFIE BLIDDAL

Speaker

10:55 - 11:15
Against for the proposal

SPYRIDOULA MARAKA

Speaker

11:15 - 12:00
Discussion

10:35 - 10:55
For the proposal

ANABELA ZUNINO

Speaker

10:55 - 11:15
Against the proposal

ROBERTO MIRASOL

Speaker

11:15 - 12:00
Discussion

10:35 - 10:55
Global iodine nutrition and thyroid diseases: Where do we stand in 2025?

RODRIGO MORENO REYES

Speaker

10:55 - 11:15
State-of-the-Art Guidelines for Monitoring Iodine Nutrition in Populations

SUN Y LEE

Speaker

11:15 - 11:30
Discussion

10:35 - 10:55
MCT8 thyroid hormone transporter and disease

EDWARD VISSER

Speaker

10:55 - 11:15
The Leptin-D2 axis controls the energy balance in Skeletal muscle

MONICA DENTICE

Speaker

11:15 - 11:30
Discussion

11:15 - 11:30
Discussion

11:15 - 11:30
Discussion

11:15 - 11:30
Discussion

12:00 - 12:20
Preview of the 2025 American Thyroid Association (ATA) nodules guidelines and how to apply to fine needle aspiration (FNA) decision making

SUSAN MANDEL

Speaker

12:20 - 12:40
Implementing active surveillance for low-risk thyroid carcinoma into clinical practice: collaborative recommendations for Latin America

CAROLINA FERRAZ

Speaker

12:40 - 13:00
Round table/ Q&A

12:00 - 12:20
Subclinical Hypothyroidism

ANA LUIZA MAIA

Speaker

12:20 - 12:40
Cardiovascular involvement in overt hypothyroidism

GABRIELA BRENTA

Speaker

12:40 - 13:00
Combined T3 +LT4 therapy vs. LT4 monotherapy in patients with hypothyroidism

BIRTE NYGAARD

Speaker

13:00 - 13:05
1112409 - PREDICTIVE FACTORS OF RADIOACTIVE IODINE-REFRACTORY EVOLUTION OF THYROID CANCER IN A PROSPECTIVE COHORT | Presenter:LAURINE MEBARKI

13:05 - 13:10
1112342 - IMPACT OF PHYSICAL ACTIVITY AND ITS MAINTENANCE IN THE EFFICACY AND SAFETY OF TYROSINE KINASE INHIBITORS IN ADVANCED THYROID CARCINOMA PATIENTS | Presenter: CARLA COLOMBO

13:10 - 13:15
1112385 - LESIONAL DOSIMETRY IN 131I REFRACTORY METASTATIC DIFFERENTIATED THYROID CANCER WITH BRAFP.V600E OR RAS MUTATION TREATED WITH TRAMETINIB +/- DABRAFENIB FOLLOWED BY HIGH ACTIVITY OF RADIOACTIVE IODINE | Presenter: SOPHIE LEBOULLEUX

13:15 - 13:20
1112183 - LONG-TERM OUTCOME FOR PAPILLARY THYROID CARCINOMA WITH LUNG METASTASIS | Presenter: IWAO SUGITANI

13:20 - 13:25
1112956 - Exposomic Analysis of Thyroid Cancer: Correlating histopathological characteristics with persistent environmental organic pollutants | Presenter: THOMAS SZABO YAMASHITA

13:25 - 13:30
1112631 - ANALYTICAL VALIDATION OF A CUSTOMIZED TARGETED RNA NGS PANEL FOR DETECTING GENETIC ALTERATIONS IN 57 RECURRENT MUTATED GENES FOR DIAGNOSIS AND PROGNOSIS OF INDETERMINATE THYROID NODULES AND THYROID CANCER | Presenter: ISABELA NOGUEIRA NUNES

13:30 - 13:35
1112329 - ASSESSMENT OF INTERNATIONAL MEDULLARY THYROID CARCINOMA GRADING SYSTEM PROGNOSIS IN PATIENTS WITH DISTANT METASTASES.| Presenter: TOMMASO PORCELLI

13:35 - 13:40
1112623 - CHALLENGES IN DETERMINING THE OPTIMAL TIMING FOR THYROID REMOVAL IN YOUNG MEN2A PATIENTS: INSIGHTS FROM TWO BRAZILIAN REFERRAL CENTERS | Presenter: LAURA MARMITT

13:40 - 13:45
1112460 - CIRCULATING MICRORNAS IN THE FOLLOW-UP OF PATIENTS WITH PAPILLARY THYROID CARCINOMA | Presenter: NATHÁLIA DA CRUZ DE SOUSA MURAD

13:45 - 13:50
1113636 - ALK Inhibition Prolongs Survival in a Mouse Model of ALK-positive Anaplastic Thyroid Cancer | Presenter: YARA MARIA MACHLAH

13:50 - 13:55
1112228 - IMMUNOMODULATORY EFFECTS OF LENVATINIB IN ADVANCED THYROID CARCINOMA | Presenter: PRASHANT CHANGOER

13:00 - 13:05
1112644 - DEFINING A CUTOFF FOR CALCITONIN LEVELS IN FINE-NEEDLE ASPIRATION WASHOUT FLUID TO EXCLUDE MEDULLARY THYROID CARCINOMA DIAGNOSIS | Presenter:GUSTAVO IVANI DE PAULA

13:05 - 13:10
1112476 - REVOLUTIONIZING BENIGN NODULE TREATMENT: THE IMPACT OF RADIOFRECUENCY ABLATION| Presenter: JORGELINA L. GUERRA

13:10 - 13:15
1112527 - TRANSFORMING PARATHYROID SURGERY: THE ROLE OF RADIOFREQUENCY ABLATION IN TREATING ADENOMAS | Presenter: ANA INES VOOGD

13:15 - 13:20
1112390 - ENHANCED ALGORITHM FOR THYROID NODULE CLASSIFICATION: PERFORMANCE COMPARISON OF MIR-THYPE V1 AND V2 | Presenter: MARCOS TADEU DOS SANTOS

13:20 - 13:25
1112275 - RADIOFREQUENCY ABLATION VERSUS ETHANOL ABLATION FOR BENIGN THYROID NODULES TREATMENT: A SYSTEMATIC REVIEW AND META-ANALYSIS | Presenter: ALINE LEVY SITNOVETER

13:25 - 13:30
1112455 - REDEFINING BETHESDA III: THE VALUE OF BINARY STRATIFICATION IN PREDICTING THYROID MALIGNANCY | Presenter:VERONICA ILERA

13:30 - 13:35
1112599 - ULTRASONOGRAPHIC-HISTOLOGICAL CORRELATION OF THYROID NODULES IN A CHILEAN CENTER AND PERFORMANCE OF ACR-TIRADS VARIABLES | Presenter: NICOLE LUSTIG FRANCO

13:35 - 13:40
1112186 - IDENTIFYING PREDICTORS OF PERMANENT HYPOPARATHYROIDISM AFTER THYROID CANCER SURGERY—A COMPREHENSIVE REAL-LIFE RETROSPECTIVE ANALYSIS | Presenter: ROSSELLA MELCARNE

13:40 - 13:45
1112242 - INTRAOPERATIVE USE OF FLUORESCENCE WITH INDOCYANINE GREEN TO PREDICT POSTOPERATIVE HYPOPARATHYROIDISM.| Presenter: RASMUS REINKE

13:45 - 13:50
1112305 - LARYNGEAL ULTRASOUND PERFORMANCE FOR THE DIAGNOSIS OF VOCAL CORD PARALYSIS POST-THYROIDECTOMY: A MULTICENTER DIAGNOSTIC TEST STUDY IN MEDELLIN, COLOMBIA. | Presenter:DAVID MAURICIO FIGUEROA BOHORQUEZ

13:50 - 13:55
1112391 - PREOPERATIVE MIR-146B EXPRESSION AS A PREDICTOR OF AGGRESSIVE OUTCOMES IN DIFFERENTIATED THYROID CARCINOMAS | Presenter: MARCOS TADEU DOS SANTOS

13:00 - 13:05
1112395 - DELIVERY OF MIR-485-5P AND MIR-495-3P VIA EXTRACELLULAR VESICLES IMPAIRS CELL MIGRATION AND INVASION IN THYROID CANCER CELLS | Presenter: MURILO VIEIRA GERALDO

13:05 - 13:10
1112387 - IN VIVO DETECTION OF THE MOLECULAR MECHANISMS OF CELL DEATH INDUCED BY CARBON ION THERAPY IN ANAPLASTIC THYROID CANCER | Presenter: PIETRO DI FAZIO

13:10 - 13:15
1112367 - METFOMIN REDUCES JAK/STAT PATHWAY ACTIVATION IN ANAPLASTIC THYROID CANCER IN MONOLAYER AND SPHEROID CELLS MODELS | PRESENTER: PALOMA RAMOS DE OLIVEIRA

13:15 - 13:20
1112399 - NIFUROXAZIDE ACTIVITY IN ANAPLASTIC THYROID CANCER: MODULATION OF CANCER STEM-LIKE CELL PROPERTIES AND THE INVOLVEMENT OF JAK/STAT3 PATHWAY | PRESENTER: GUSTAVO FELISOLA CASO

13:20 - 13:25
1112561 - SERUM MICRORNA ANALYSIS FACILITATES THE DECISION BETWEEN ACTIVE SURVEILLANCE AND IMMEDIATE SURGERY OF THYROID MICROCARCINOMA | PRESENTER:FERNANDA FARO

13:25 - 13:30
1112284 - STUDY ON THE ROLE AND MECHANISM OF MIOX IN REGULATING FERROPTOSIS IN PAPILLARY THYROID CARCINOMA | PRESENTER:SONGBO

13:30 - 13:35
1112306 - TARGETING PI3K/AKT/MTOR SIGNALING AND INHIBITION OF BCR/ABL TYROSINE KINASE AND GLUCOSE UPTAKE OVERCOMES RESISTANCE TO LENVATINIB IN THYROID CANCER | PRESENTER:SONAM KUMARI

13:35 - 13:40
1112572 - THE PHENOTYPE CORRELATED WITH NON CYSTEINE RET GERMLINE MUTATION IS CHARACTERIZED BY THE PRESENCE OF MEDULLARY THYROID CANCER ALONE | PRESENTER: Cristina Romei

13:40 - 13:45
1112601 - TRACING THE MOLECULAR ROUTE TO PROGRESSION IN DEFECTIVE MIRNA BIOGENESIS THYROID LESIONS | PRESENTER:BARBARA RIVERA POLO

13:45 - 13:50
1112265 - HETEROGENEITY OF MYELOID CELLS IN ANAPLASTIC THYROID CANCER: WHEN “NICHES” MATTER | PRESENTER: CORNUOT CLÉMENCE

13:00 - 13:05
1112436 - INFILTRATED MACROPHAGES CONTRIBUTE TO CARDIAC HYPERTROPHY ASSOCIATED WITH HYPERTHYROIDISM | PRESENTER: NATHALIA SENGER

13:05 - 13:10
1112560 - NEUTROPENIA IN CHILDREN WITH GRAVES‘ DISEASE TREATED WITH METHIMAZOLE: A CHINESE CHILDREN COHORT (3C) STUDY | PRESENTER: SHI TANG

13:10 - 13:15
1112530 - RESTING CARDIAC SYMPTOMS CAN PERSIST IN PATIENTS WITH GRAVES’ DISEASE TREATED TO STABLE EUTHYROIDISM | PRESENTER:ANOUK VAN HALL

13:15 - 13:20
1112364 - TIME-DEPENDENT CHANGES OF THE RISK OF ATRIAL FIBRILLATION IN PATIENTS WITH HYPERTHYROIDISM RECEIVING RADIOACTIVE IODINE TREATMENT COMPARING TO ANTI-THYROID DRUG: A NATIONWIDE COHORT STUDY | PRESENTER:KYEONG JIN KIM

13:20 - 13:25
1112282 - RELATIONSHIP BETWEEN SERUM LEVELS OF SIROLIMUS (RAPAMYCIN) AND OUTCOME OF MODERATE-TO-SEVERE, ACTIVE GRAVES’ ORBITOPATHY | MICHELE MARINO

13:25 - 13:30
1112533 - SPECIFIC INTRA-ORBITAL FAT AND MUSCLE LYMPHOCYTE INFILTRATES ARE ASSOCIATED WITH DIFFERENT CLINICAL MANIFESTATIONS OF THYROID EYE DISEASE | PRESENTER: ILARIA MULLER

13:30 - 13:35
1112239 - COMPARATIVE ANALYSIS OF ORBITAL TISSUE MICROENVIRONMENTS IN ACTIVE VERSUS INACTIVE THYROID EYE DISEASE: A SINGLE-CELL TRANSCRIPTOMICS APPROACH | PRESENTER: YUANPING HAI

13:35 - 13:40
1112238 - HIGH-THROUGHPUT PROTEOMICS COMBINED WITH IMMUNOHISTOCHEMISTRY OF ORBITAL CONNECTIVE TISSUE IN THYROID EYE DISEASE | PRESENTER:YUANPING HAI

13:40 - 13:45
1112503 - TWENTY-YEAR SECULAR TREND OF THYROTOXICOSIS AND THYROTOXIC PERIODIC PARALYSIS IN HONG KONG | PRESENTER: GLORIA HOI-YEE LI

13:45 - 13:50
1112363 - THERMOGRAPHIC ASSESSMENT OF THYROID EYE DISEASE IN RESPONSE TO STEROID THERAPY | PRESENTER: IVANA LOPES ROMERO KUSABARA

13:50 - 13:55
1112664 - MOLECULAR AND CLINICAL UPDATE IN THYROTOXIC PERIODIC PARALYSIS: A COMPREHENSIVE 30-YEAR STUDY OF A LARGE BRAZILIAN COHORT | PRESENTER:SUSAN CHOW LINDSEY

14:45 - 15:00
1112369 - CLINICAL AND PATHOLOGICAL CHARACTERISTICS OF DIFFERENTIATED THYROID CANCER ACCORDING TO DISTANT METASTASIS STATUS | Presenter: Lenara Golbert

15:00 - 15:15
1112243 - REAL WORLD RESULTS OF IMMUNE CHECKPOINT BLOCKERS IN ANAPLASTIC THYROID CARCINOMA PATIENTS: INSIGHT FROM THE COMEDIMS COMPASSIONATE PROGRAM AT GUSTAVE ROUSSY | Presenter: JULIEN HADOUX

15:15 - 15:30
1112439 - SURGERY FOR THYROID CANCER WITH OR WITHOUT AUTOFLUORESCENCE TO PREVENT HYPOPARATHYROIDISM – A RANDOMIZED, CONTROLLED TRIAL | Presenter:JACOB LILJA-FISCHER

15:30 - 15:45
1112557 - THE ROLE OF ADJUVANT VOLUMETRIC MODULATED ARC RADIOTHERAPY (VMAT) IN THE TREATMENT OF LOCALLY ADVANCED DIFFERENTIATED THYROID CANCER: A SINGLE INSTITUTION EXPERIENCE | Presenter: CHIARA MURA

14:45 - 15:00
1113894 - Efficacy and Safety of Veligrotug (VRDN-001), a Full Antagonist Humanized Monoclonal Antibody to IGF-1 Receptor, in Chronic Thyroid Eye Disease (TED): THRIVE-2 Phase 3 Results at 15 Weeks | PRESENTER:PATRICE RODIEN

15:00 - 15:15
1114060 - Predicting Reoperation Outcomes in Papillary Thyroid Carcinoma Using Interpretable Machine Learning| PRESENTER:ZIMEI TANG

15:15 - 15:30
1114099 - TREATMENT OF CHRONIC HYPOPARATHYROIDISM POST THYROID CANCER SURGERY THROUGH INTER VIVO PARATHYROID TRANSPLANTATION | PRESENTER: LEONARDO KRUSCHEWSKY

15:30 - 15:45
1112357 - TRAB DYNAMICS AND SURGICAL OUTCOMES IN GRAVES‘ ORBITOPATHY: A RETROSPECTIVE ANALYSIS | PRESENTER: LAURA DELFINO

14:45 - 15:00
1112250 - PATIENT-DERIVED HIPSC MODEL OF HUMAN BRAIN REVEAL MOLECULAR MECHANISMS OF CLINICAL CONSEQUENCES OF CEREBRAL SBP2 DEFICIENCY | PRESENTER: ULGU ARSLAN-VAN BERGEN

15:00 - 15:15
1112513 - PHENYLBUTYRATE INCREASES THYROXINE UPTAKE IN PRIMARY ASTROCYTES FROM MICE CARRYING A MCT8 MISSENSE MUTATION| PRESENTER: DOREEN BRAUN

15:15 - 15:30
1112197 - RHGH PARTIALLY IMPROVES CORTICAL AND HIPPOCAMPAL DEVELOPMENTAL IMPAIRMENTS IN TRΑ1 MUTANT MICE BY RESTORING THE GH/IGF-1 AXIS | PRESENTER:YANG LI

15:30 - 15:45
1112314 - THE RELEVANCE OF CO-REPRESSOR BINDING FOR THE RESISTANCE TO THYROID HORMONE ALPHA PHENOTYPE AS REVEALED BY A FAMILY CARRYING AN H175R VARIANT IN THE THYROID HORMONE RECEPTOR ALPHA | PRESENTER: MARCEL MEIMA

14:45 - 15:00
1112461 - ANAPLASTIC THYROID CANCER CELL-SECRETED TGFΒ1 UPREGULATES THE EXPRESSION OF THE IMMUNE CHECKPOINT TIM3 IN HUMAN MONOCYTES | PRESENTER: AGUSTINA JAROSZEWSKI

15:00 - 15:15
1113747 - BISPHENOL-A EXPOSURE MAY BE RELATED TO THE GROWING INCIDENCE OF THYROID TUMORS AND THE OCCURRENCE OF MORE AGGRESSIVE CANCER TYPES | PRESENTER: ELISANGELA DE SOUZA TEIXEIRA

15:15 - 15:30
1113896 - CELL INTRINSIC IFN-I SIGNATURE CORRELATES WITH DEDIFFERENTIATION OF THYROID CANCER AND DETERMINES ITS IMMUNOLOGICAL FATE | PRESENTER: TIM BRANDENBURG

15:30 - 15:45
1112581 - UNRAVELING THYROID CANCER ORIGINS: A CUTTING-EDGE HUMAN THYROID ORGANOID MODEL | PRESENTER: EDUARDO ANDRÉS RIOS MORRIS

14:45 - 15:00
1112344 - ASSOCIATION OF PERCHLORATE, THIOCYANATE, AND NITRATE WITH GESTATIONAL THYROID FUNCTION AND CHILD NEURODEVELOPMENT | PRESENTER: YINDI LIU

15:00 - 15:15
1112606 - CHARACTERIZATION AND IMPACT OF THE GESTATIONAL HYPOTHYROXINEMIC ENVIRONMENT ON MACROPHAGE POLARIZATION AND FUNCTION. | PRESENTER: EVELYN L. JARA FERNÁNDEZ

15:15 - 15:30
1112316 - THE FCRN INHIBITOR, BATOCLIMAB, RAPIDLY NORMALIZES THYROID FUNCTION IN GRAVES‘ HYPERTHYROIDISM: A PROOF-OF-CONCEPT STUDY | PRESENTER: GEORGE KAHALY

15:30 - 15:45
1112518 - THE IMPACT OF TRAB ON GUT MICROBIOTA AND NON-TARGET METABOLITES IN HUMAN AND MURINE MODEL WITH THYROID EYE DISEASE |PRESENTER: YANAN WANG

16:00 - 16:25
Indications for Active surveillance

YASUHIRO ITO

Speaker

16:25 - 16:50
Less than total thyroidectomy: indications for hemithyroidectomy or RFA

JUAN PABLO DUENAS

Speaker

16:50 - 17:15
Dynamic risk stratification, indications for completion thyroidectomy & RAI

ELIZABETH GRUBBS

Speaker

17:15 - 17:30
Discussion

16:00 - 16:25
Thyroid hormone and brain development

ANA GUADANO-FERRAZ

Speaker

16:25 - 16:50
Thyroid hormone transporters and deiodinases in development

FEDERICO SALAS-LUCIA

Speaker

16:50 - 17:15
Thyroid hormone and neuronal differentiation in organoids

ROBERT OPITZ

Speaker

17:15 - 17:30
Discussion

16:30 - 16:50
Discussion

16:30 - 16:50
Discussion

16:00 - 16:25
Performance of different US classification systems

TREVOR ANGELL

Speaker

16:25 - 16:50
Application of AI in thyroid nodule imaging

JIN YOUNG KWAK

Speaker

16:50 - 17:15
Contrast enhance imaging /elastography

RICARDO MIGUEL COSTA DE FREITAS

Speaker

17:15 - 17:30
Discussion

16:00 - 16:25
Thyroid storm in pregnancy

ULLA FELDT-RASMUSSEN

Speaker

16:25 - 16:50
Iodide for the management of hyperthyroidism in pregnancy

AI YOSHIHARA

Speaker

16:50 - 17:15
Management in the post-partum

ELIZABETH PEARCE

Speaker

17:15 - 17:30
Discussion

07:00 - 08:25
Representative for ATA

MARIA REGINA CASTRO

Panelist

07:00 - 08:25
Representative for ETA

COSIMO DURANTE

Panelist

07:00 - 08:25
Representative for AOTA

HARUHIKO YAMAZAKI

Panelist

07:00 - 08:25
Representavive for LATS

RAFAEL SELBACH SCHEFFEL

Panelist

09:45 - 10:10
Advances in Medullary Thyroid Cancer

MIMI HU

Speaker

10:10 - 10:35
Redifferentiation therapy

SOPHIE LEBOULLEUX

Speaker

10:35 - 11:00
Neoadjuvant therapy

INES CALIFANO

Speaker

11:00 - 11:10
Discussion

09:45 - 10:10
Thyroid hormone and genomic regulation in amphibians

LAURENT SACHS

Speaker

10:10 - 10:35
Thyroid hormone and circadian control

PAULA BARGI SOUZA

Speaker

10:35 - 10:45
Discussion

09:45 - 10:10
The structure, function, and mechanism of the Na+/I- symporter (NIS)

NANCY CARRASCO

Speaker

10:10 - 10:35
Iodine prophylaxis and its impact on thyroid diseases

PETER KOPP

Speaker

10:35 - 11:00
Selenium and thyroid function: what is new

SUN WOOK CHO

Speaker

11:00 - 11:10
Discussion

10:15 - 10:35
Discussion

09:45 - 10:10
Patients with THRA and THRB receptor defects

CARLA MORAN

Speaker

10:10 - 10:35
Thyroid hormone and the immune system

MARIA DEL MAR MONTESINOS

Speaker

10:35 - 10:45
Discussion

09:45 - 10:10
How genetics can modify the diagnosis and management of CH

NADIA SCHOENMAKERS

Speaker

10:10 - 10:35
Functional noncoding variants as new cause of CH

HELMUT GRASBERGER

Speaker

10:35 - 11:00
Dealing with variants of uncertain significance in the genetic diagnosis of congenital hypothyroidism

JUAN PABLO NICOLA

Speaker

11:00 - 11:10
Discussion

09:45 - 10:25
Screening YES/NO

LAURA FUGAZZOLA

Speaker

10:25 - 10:35
Discussion

11:20 - 11:30
Discussion

11:45 - 12:00
Discussion

11:45 - 12:00
Discussion

11:15 - 11:45
The Effects of Radiation Exposure on the Thyroid Gland in Fukushima, Japan

HIROKI SHIMURA

Speaker

11:45 - 12:00
Discussion

13:00 - 13:05
1112394 - PROGNOSTIC VALUE OF RET STATUS IN PATIENTS WITH UNRESECTABLE MEDULLARY THYROID CANCER TREATED BY VANDETANIB: THE PRONOMED STUDY | Presenter: NOÉMIE SIMON-TILLAUX

13:05 - 13:10
1112624 - MOLECULAR CHARACTERIZATION OF A LARGE SERIES OF SUBCENTIMETRIC PAPILLARY THYROID CARCINOMAS | Presenter: ELISABETE OLIVEIRA TEIXEIRA

13:10 - 13:15
1114103 - The Genomic Landscape of 250,000+ Thyroid Nodules Undergoing Exome-enriched RNA Sequencing | Presenter: Sarah Hamidi

13:15 - 13:20
1112612 - SAFETY AND EFFICACY OF SELPERCATINIB TREATMENT IN ADVANCED MEDULLARY THYROID CANCER PATIENTS: A REAL-LIFE STUDY | Presenter:ANTONIO MATRONE

13:20 - 13:25
1112424 - ULTRASOUND-GUIDED CRYOABLATION, LASER OR RADIOFREQUENCY ABLATION OF CERVICAL METASTASES FROM THYROID CARCINOMA: A PROSPECTIVE CLINICAL TRIAL | Presenter:RICARDO MIGUEL COSTA DE FREITAS

13:25 - 13:30
1112312 - VALIDATION OF THE INTERNATIONAL MEDULLARY THYROID CANCER GRADING SYSTEM AND IDENTIFICATION OF EZH2 AS A PROGNOSTIC AND POTENTIAL THERAPEUTIC MARKER IN MEDULLARY THYROID CANCER PATIENTS | Presenter: Thera Links

13:30 - 13:35
1112193 - VASCULAR INVASION AS A PREDICTOR OF DISTANT RECURRENCE IN FOLLICULAR CARCINOMAS: ARE THE DEFINITIONS OF ‘WIDELY INVASIVE FOLLICULAR CARCINOMA‘ AND ‘ENCAPSULATED ANGIOINVASIVE FOLLICULAR CARCINOMA‘ APPROPRIATE? | Presenter: YASHURO ITO

13:35 - 13:40
1114005 - Lenvatinib treatment as a neoadjuvant option in locally advanced thyroid cancer | Presenter: ALEJANDRO ROMAN GONZALEZ

13:40 - 13:45
1113739 - Unstimulated Postoperative Thyroglobulin Is Highly Accurate In Predicting Treatment Response In High-Risk Differentiated Thyroid Cancer Patients - A Retrospective Cohort Study | Presenter: JULIA ISABEL RICHTER CICOGNA

13:45 - 13:50
1112619 - ANAPLASTIC THYROID CANCER UNDERGOES GENOMIC AND PHENOTYPIC PLASTICITY IN RESPONSE TO BRAF INHIBITOR TREATMENT | Presenter: XIAO ZHAO

13:00 - 13:05
1112526 - THE NLRP3/TLR2/NFΚB PATHWAY IS INVOLVED IN THE OCCURRENCE OF MISCARRIAGE IN AIT PATIENTS

13:05 - 13:10
1112372 - FUNCTIONAL ANALYSIS OF SLC5A5 GENE VARIANTS ASSOCIATED WITH CONGENITAL HYPOTHYROIDISM | PRESENTER:GERARDO HERNÁN CARRO

13:10 - 13:15
1112321 - FUNCTIONAL TESTING OF POTENTIAL NOVEL THYROID HORMONE TRANSPORTERS INFORMED BY A LARGE SCALE THYROID FUNCTION GENOME-WIDE ASSOCIATION STUDY | MATTHIJS FREUND

13:15 - 13:20
1113717 - GESTATIONAL HYPOTHYROXINEMIA DAMAGES THE INTESTINAL INTEGRITY IN THE ILEUM OF THE ADULT OFFSPRING | MARIA JOSE MENDOZA LEON

13:20 - 13:25
1112598 - TRIIODOTHYRONINE MODULATES DENDRITIC CELL-DERIVED EXTRACELLULAR VESICLES AND THEIR ROLE IN IMMUNE RESPONSE REGULATION | MARIANA PIRES CAVALCANTI TEIXEIRA

13:25 - 13:30
1112374 - PATHOGENIC VARIANTS IN CONSERVED RESIDUES OF SLC5A FAMILY MEMBERS REVEALED KEY RESIDUES FOR NIS FUNCTION | GERARDO HERNÁN CARRO

13:30 - 13:35
1112276 - NEW INSIGHTS INTO THYROID HORMONE METABOLISM AND AMMONIA DETOXIFICATION IN MASLD USING N-ACETYLCYSTEINE (NAC) AND L-ORNITHINE L-ASPARTATE (LOLA) | CAROLINA NADVORNY

13:40 - 13:45
1114179 - Chronic iodine excess induced TSH elevation by inactivating Type 2 deiodinase via ROS/AKT-mTOR-GSK3β/NRF2 signaling pathway | XIAOTONG GAO

13:45 - 13:50
1112292 - IFNΑ TRIGGERS AUTOIMMUNE THYROIDITIS BY RESHAPING THYROGLOBULIN IMMUNOGENIC PEPTIDE REPERTOIRE| MIHAELA STEFAN LIFSHITZ

13:50 - 13:55
1112184 - INTEGRATED TRANSCRIPTOMIC AND EPIGENETIC PROFILING OF THYROCYTES IN AUTOIMMUNE THYROIDITIS VIA SINGLE CELL RNA-SEQ, BULK RNA-SEQ AND DNA METHYLATION PROFILING | TINGTING LIU

13:05 - 13:10
1112254 - HISTONE ACETYLTRANSFERASE LOSS-OF-FUNCTION PROMOTES THYROID CANCER PROGRESSION IN VIVO AND SENSITIZES HUMAN THYROID CANCER CELLS TO HIGHLY SPECIFIC PROTEIN DEGRADERS Presenter: IÑIGO LANDA

13:10 - 13:15
1112515 - BISPHENOL A, PERCHLORATE, AND NITRATE MIXTURE DISRUPTS CELL DIFFERENTIATION AND ALTERS EPIGENETIC MECHANISMS AND SIGNALING PATHWAYS IN THYROCYTES | PRESENTER: EVELYN FRANCINY CARDOSO TAVARES

13:15 - 13:20
1112589 - FOXE1 DOMAINS AT THE CROSSROAD BETWEEN EVOLUTION AND THYROID FUNCTIONALITY| PRESENTER:ELISA STELLARIA GRASSI

13:20 - 13:25
1112446 - HYPOTHYROIDISM PROMOTES A SARCOPENIA-LIKE PHENOTYPE IN YOUNG BUT NOT IN AGED MICE | PRESENTER:THAMIRES SIQUEIRA DE OLIVEIRA

13:25 - 13:30
1112233 - DEVELOPING A TESTING BATTERY FOR DEVELOPMENTAL NEUROTOXICITY MEDIATED VIA DISRUPTED THYROID HORMONE HOMEOSTASIS | PRESENTER:NATHALIE DIERICHS

13:30 - 13:35
1112514 - MATERNAL EXPOSURE TO TRICLOSAN DURING THE INTRAUTERINE PERIOD DISRUPTS THYROID DEVELOPMENT AND FUNCTION IN THE OFFSPRING ANIMALS | PRESENTER:GUILHERME HENRIQUE

13:35 - 13:40
1112511 - POLYCHLORINATED BIPHENYLS DISRUPT GENE EXPRESSION, NIS FUNCTION, AND KEY SIGNALING PATHWAYS IN HUMAN THYROID CELLS | PRESENTER:VINICIUS GONÇALVES RODRIGUES

13:40 - 13:45
1112360 - TRANSCRIPTOMIC PROFILING OF THYROID CELLS EXPOSED TO ROUNDUP® ORIGINAL DI REVEALS DOSE-DEPENDENT EFFECTS: IMPLICATIONS FOR SAFETY STANDARDS | PRESENTER: Sophia de Alcantara

13:45 - 13:50
1113992 - DEHAL1 modulates oxidative stress induced by endogenous and anthropogenic oxidants. | PRESENTER: José C. Moreno

13:50 - 13:55
1112208 - THE ROLE OF THYROID HORMONE IN SUSCEPTIBILITY TO TYPE 2 DIABETES IN OFFSPRING: REGULATORY MECHANISMS OF THE PLACENTAL GENOMIC IMPRINT AT THE DLK1-DIO3 LOCUS IN WOMEN WITH HYPOTHYROIDISM. | PRESENTER: MARIA BEATRIZ BRAVIN

13:00 - 13:05
1112209 - CARDIAC COMPLICATIONS IN PATIENTS WITH RESISTANCE TO THYROID HORMONE DUE TO THYROID HORMONE RECEPTOR BETA GENE MUTATIONS (RTHΒ) | PRESENTER: NATSUKO WATANABE

13:05 - 13:10
1112223 - THE IMPACT OF HEALTH LITERACY ON HYPOTHYROIDISM MANAGEMENT IN PATIENTS UNDERGOING LEVOTHYROXINE THERAPY | PRESENTER:JESSYKA

13:10 - 13:15
1112656 -IODINE, HEAVY METALS, AND THYROID FUNCTION IN PREGNANCY: A CROSS-SECTIONAL STUDY IN BOTUCATU, BRAZIL.| PRESENTER: ADRIANO FRANCISCO DE MARCHI JUNIOR

13:15 - 13:20
1112508 - MILD IODINE DEFICIENCY DURING THE INTRAUTERINE PERIOD DISRUPTS THE PITUITARY-THYROID AXIS OF THE OFFSPRING DURING ADULT LIFE | PRESENTER: THACILA DE OLIVEIRA MARQUES

13:20 - 13:25
1112574 - MATERNAL HYPOTHYROXINEMIA IN EARLY PREGNANCY AND OFFSPRING NEURODEVELOPMENT: A PROSPECTIVE INTERVENTION STUDY | PRESENTER: YUTONG HAN

13:25 - 13:30
1112225 - NEWBORN SCREENING FOR CONGENITAL HYPOTHYROIDISM: WORLDWIDE COVERAGE 50 YEARS AFTER ITS START | PRESENTER: CHRISTIAAN MOOIJ

13:30 - 13:35
1112611 - IODINE STATUS QUESTIONNAIRE ASSESSMENT DURING PREGNANCY: A PILOT STUDY. | PRESENTER: MARIA IZABEL CHIAMOLERA

13:35 - 13:40
1112323 - TREATMENT PATTERNS AMONG METHIMAZOLE-TREATED PATIENTS WITH GRAVES’ DISEASE | PRESENTER: Marius Stan

13:40 - 13:45
1112418 - THYROID AUTOIMMUNITY AND PREGNANCY: IMPLICATIONS FOR MATERNAL AND FETAL HEALTH OUTCOMES | CAMILA BERGER DE OLIVEIRA CUNHA

13:45 - 13:50
1112587 - CLINICAL IMPLICATIONS FOR OBESITY MANAGEMENT: BARIATRIC SURGERY-INDUCED CHANGES IN TSH AND ITS CORRELATION WITH THE NEW MODEL OF OBESITY CLASSIFICATION PROPOSAL BY SBEM/ABESO, A CROSS SECTIONAL STUDY. | PRESENTER:ADRIANO FRANCISCO DE MARCHI JUN

13:50 - 13:55
1114292 - Subclinical hypothyroidism as a risk for coronary artery bypass grafting | PRESENTER: GIOVANNA APARECIDA BALARINI LIMA

14:45 - 15:00
1112621- A TUMOR-CELL SPECIFIC GENE SIGNATURE DERIVED FROM SINGLE-CELL SEQUENCING IS PROGNOSTIC ACROSS INDEPENDENT COHORTS OF PAPILLARY THYROID CARCINOMA PATIENTS | PRESENTER: JENNIFER RUI WANG

15:00 - 15:15
1112553 - GENETIC ANCESTRY OF RET MUTATIONS AT CODON 804 REVEALS A BOTTLENECK EFFECT AMONG BRAZILIANS WITH MULTIPLE ENDOCRINE NEOPLASIA TYPE 2 | PRESENTER: FELIPE RODRIGUES BETONI

15:15 - 15:30
1112616 - MOLECULAR PROFILE OF ADVANCED RADIOIODINE-REFRACTORY THYROID CANCER AND RESPONSE TO LENVATINIB TREATMENT | PRESENTER: ELISA MINALDI

15:30 - 15:45
1112244 - THE SIGNIFICANCE OF APOPTOSIS DYSREGULATION IN CLINICAL MANAGEMENT OF PAPILLARY THYROID CANCER: IDENTIFICATION OF NOVEL THERAPEUTIC TARGETS | PRESENTER: ADAMSKA AGNIESZKA

14:45 - 15:00
1114004 - TOCILIZUMAB VS METHYLPREDNISOLONE IN MODERATE-SEVERE GRAVES' ORBITOPATHY: RESULTS OF AN ITALIAN MULTICENTER CLINICAL TRIAL | PRESENTER: MARIO SALVI

15:00 - 15:15
1112453 - DISEASE PRESENTANTION AND DISTINCT GENETIC PROFILES ARE RELATED TO GENDER AND PUBERTY COMPLETION IN PEDIATRIC DIFFERENTIATED THYROID CARCINOMA | PRESENTER: Paulo Alonso Garcia Alves

15:15 - 15:30
1112255 - NEWBORNS THYROGLOBULIN IS A MORE SENSITIVE BIOMARKER FOR MONITORING IODINE STATUS THAN NEONATAL TSH | PRESENTER: CAMILO FUENTES PEÑA

14:45 - 15:00
1112486 - EVALUATING INSULIN‘S IMPACT ON THYROID DEVELOPMENT USING HUMAN THYROID ORGANOIDS | PRESENTER: SABINE COSTAGLIOLA

15:00 - 15:15
1112269 - INDUCTION OF TYPE 2 AND 3 DEIODINASES IN MUSCLE STEM CELLS OF CRITICALLY ILL PATIENTS: UNVEILING THE IMPLICATIONS FOR HYPERGLYCEMIA AND NON-THYROIDAL ILLNESS SYNDROME | PRESENTER: Thaliane Carvalho Oliveira

15:15 - 15:30
1112499 - UNREVEALING THE EPIGENETIC MECHANISMS TRIGGERED BY TSH IN THE STIMULATION OF THYROID DIFFERENTIATION MARKERS GENE EXPRESSION| PRESENTER:VINICIUS GONÇALVES RODRIGUES

15:30 - 15:45
1113824 - Identification and Characterization of GC-Cells: A Novel Population of Benign Epithelial Cells Involved in Lymph Node Metastasis of Papillary Thyroid Carcinoma | PRESENTER: YEFENG CAI

14:45 - 15:00
1112222 - AN UNBIASED, AI-DRIVEN, QUANTITATIVE SURVEY OF HISTOLOGY IN HUMAN ASYMPTOMATIC THYROIDS REVEALS THE EXTENT OF NATURAL MORPHOLOGICAL VARIATION AND HISTOLOGICAL QTLS | PRESENTER: VINCENT DETOURS

15:00 - 15:15
1112207 - CORE-NEEDLE BIOPSY IS A SAFE AND VALUABLE OPTION. FIRST 532 PROCEDURES IN ROMANIA | PRESENTER: EMIN MAMMADOV

15:15 - 15:30
1112465 - RESULTS OF A SERIES OF 167 CASES OF MICROWAVE ABLATION FOR BENIGN THYROID NODULES | PRESENTER: CARLOS NEUTZLING LEHN

15:30 - 15:45
1114232 - Prospective results for active surveillance of RAS-positive indeterminate thyroid nodules with Bethesda III and IV cytologies | PRESENTER: MARKUS ESZLINGER

14:45 - 15:00
1112368 - ASSOCIATION BETWEEN SUBCLINICAL HYPOTHYROIDISM AND CHRONIC KIDNEY DISEASE INCIDENCE: INSIGHTS FROM ELSA-BRASIL | PRESENTER: DANIELLA ARAUJO MUNIZ

15:00 - 15:15
1112232 - DIFFERENT INHIBITING MECHANISMS OF AN ANTI-IGF-1R SMALL MOLECULE VERSUS AN ANTI-IGF-1R MONOCLONAL ANTIBODY | PRESENTER: GEORGE KAHALY

15:15 - 15:30
1112417 -IMPACT OF ENDOCRINE DISRUPTORS ON THYROID FUNCTION AND REPRODUCTIVE HEALTH: INSIGHTS INTO THE HYPOTHALAMIC-PITUITARY-THYROID AXIS | PRESENTER: CAMILA BERGER DE OLIVEIRA CUNHA

15:30 - 15:45
1112313 - MULTIPLE ASSAY INTERFERENCES LEADING TO THE DIAGNOSIS OF LYMPHOPROLIFERATIVE DISORDERS | PRESENTER: IRENE CAMPI

16:00 - 16:25
Active surveillance for indeterminate thyroid nodules

ALVARO SANABRIA

Speaker

16:25 - 16:50
Minimally invasive management of thyroid nodules

GIOVANNI MAURI

Speaker

16:50 - 17:15
Endoscopic surgery

ANTONIO BERTELLI

Speaker

17:15 - 17:30
Discussion

16:00 - 16:25
Human radiation exposure and thyroid genetic alterations

ROSSELLA ELISEI

Speaker

16:25 - 16:50
Chemical disruptors and neonatal screening

CAROLINE SERRANO DO NASCIMENTO

Speaker

16:50 - 17:15
Endocrine Disruptors in Thyroid Disease

AARTI MATHUR

Speaker

17:15 - 17:30
Discussion

16:00 - 16:30
Understanding the mechanisms behind the disorders

SIMONE WAJNER

Speaker

16:30 - 16:50
Discussion

16:00 - 16:25
TERT promoter mutations as a driver of tumor aggression

NORISATO MITSUTAKE

Speaker

16:25 - 16:50
Tumor Microenvironment in thyroid cancer differentiation

LAURA FOZZATTI

Speaker

16:50 - 17:15
The Role of Deiodinases in Thyroid Tumorigenesis

DOMENICO SALVATORE

Speaker

17:15 - 17:30
Discussion

16:00 - 16:25
Heart and vascular risk

JOSE SGARBI

Speaker

16:25 - 16:50
Bones and fracture risk

ROBIN PEETERS

Speaker

16:50 - 17:15
Mental health and cognition

ANNE CAPPOLA

Speaker

17:15 - 17:30
Discussion

08:00 - 08:20
Maternal hypothyroxinaemia: treat or observe

TIM KOREVAAR

Speaker

08:20 - 08:40
Autoimmunity with assisted reproduction

KRIS POPPE

Speaker

08:40 - 09:00
Uncontrolled Graves' disease

DANILO VILLAGELIN

Speaker

09:00 - 09:20
Treatment of MCT8 Deficiency during Pregnancy

STEFAN GROENEWEG

Speaker

09:20 - 09:30
Discussion

10:30 - 10:50
North America/Canada

MARKUS ESZLINGER

Speaker

10:50 - 11:10
Europe

CARLA COLOMBO

Speaker

11:10 - 11:30
Asia

KENNICHI KAKUDO

Speaker

11:30 - 11:50
Latin America

CAROLINA FERRAZ

Speaker

11:50 - 12:00
Discussion

10:30 - 10:50
For the proposal

KRISTIEN BOELAERT

Speaker

10:50 - 11:10
Against the proposal

PRIYA DEDHIA

Speaker

11:10 - 12:00
Discussion

10:30 - 10:55
Thyroid hormone transport and the CNS

Heike Heuer

Speaker

10:55 - 11:20
Deiodinases and brain function

ARTURO HERNANDEZ

Speaker

11:20 - 11:45
Thyroid hormone and neuronal differentiation

FREDERIC FLAMANT

Speaker

11:45 - 12:00
Discussion

10:30 - 10:55
Selenium and vitamin D in Hashimoto thyroiditis

JEREMYJONES FERNANDEZ ROBLES

Speaker

10:55 - 11:20
Microbiome in thyroid autoimmunity

CAMILLA VIRILI

Speaker

11:20 - 11:45
Stress and lifestyle in pathogenesis of AITD

LEONIDAS DUNTAS

Speaker

11:45 - 12:00
Discussion

10:30 - 10:55
Oncocytic thyroid cancer: new lessons from an old tumor

DEBORA DANILOVIC

Speaker

10:55 - 11:20
Clinical utility of micro RNA expression

EDNA T. KIMURA

Speaker

11:20 - 11:45
Mechanisms of development of drug resistance to targeted therapies

NAIFA LAMKI BUSAIDY

Speaker

11:45 - 12:00
Discussion

10:30 - 10:55
Metabolic and lipid effects

GABRIELA BRENTA

Speaker

10:55 - 11:20
Thyroid hormone agonists in metabolic liver disease

DAGMAR FUEHRER

Speaker

11:20 - 11:45
Management of refractory hypothyroidism

IRENE CAMPI

Speaker

11:45 - 12:00
Discussion

13:00 - 13:20
YES

JANETE MARIA CERUTTI

Speaker

13:20 - 13:50
NO

MATTHEW DAVID RINGEL

Speaker

13:50 - 14:00
Discussion

13:00 - 13:30
Subclinical Hyperthyroidism: Treat or observe?

JENNIFER MAMMEN

Speaker

13:30 - 13:50
Discussion

13:00 - 13:30
Thyroid dysfunction with Immune Checkpoint inhibitors

MARIA FABIANA RUSSO PICASSO

Speaker

13:30 - 13:50
Discussion

13:00 - 13:20
Update on T4 monotherapy and the HPT axis

ANTONIO C BIANCO

Speaker

13:20 - 13:40
Hypothalamic control of the thyroid axis

CSABA FEKETE

Speaker

13:40 - 14:00
Discussion

13:30 - 13:50
Discussion

13:00 - 13:25
Long-term impact of in utero thyroid hormone exposure

MARGARET ZACHARIN

Speaker

13:25 - 13:50
Long-term impact of in utero thyroid hormone exposure

ALEXANDRA DUMITRESCU

Speaker

13:50 - 14:15
Hazards of hyperthyroidism and antithyroid drugs

MARIO ROTONDI

Speaker

14:15 - 14:30
Discussion

13:30 - 13:50
Discussion